In the BioHarmony Drug Report Database

"Preview" Icon

Etelcalcetide

Parsabiv (velcalcetide) is a protein pharmaceutical. Velcalcetide was first approved as Parsabiv on 2016-11-11. It has been approved in Europe to treat secondary hyperparathyroidism. It is known to target extracellular calcium-sensing receptor. Parsabiv’s patents are valid until 2034-06-27 (FDA).

 

Trade Name

 

Parsabiv
 

Common Name

 

velcalcetide
 

ChEMBL ID

 

CHEMBL3545184
 

Indication

 

secondary hyperparathyroidism
 

Drug Class

 

Peptides

Image (chem structure or protein)

Etelcalcetide structure rendering